Lithium Therapy in Patients with Kidney Disease

Introduction to Lithium Pharmacokinetics

• The American Kidney Foundation recommends monitoring serum creatinine and estimated GFR at baseline, then at 2-4 weeks after initiation, and continue regular monitoring throughout treatment 1

Dosing Considerations for Renal Impairment

• The National Kidney Foundation suggests that patients with kidney disease require significantly lower lithium doses and may need dosing adjustments based on GFR, with particular caution when GFR falls below 60 mL/min 2

Critical Monitoring and Dose Adjustments

• The FDA emphasizes that adequate fluid intake and normal salt intake are essential during the initial stabilization period, and patients on dialysis should monitor pre-dialysis serum lithium concentrations for at least two weeks after treatment initiation due to the "rebound effect" from lithium's two-compartment distribution 1